DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646
Cephradine is a semisynthetic cephalosporin antibiotic. Cephradine is active against the following organisms in vitro: Group A beta-hemolytic streptococci; Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing strains; Streptococcus pneumoniae (formerly Diplococcus pneumoniae); Escherichia coli; Proteus mirabilis; Klebsiella species; Hemophilus influenza. It works by stopping the growth of bacteria. It is used to treat a wide variety of bacterial infections (e.g., skin, ear, respiratory and urinary tract infections). Pseudomembranous colitis has been reported in patients receiving cephradine both orally and intravenously. Diarrhea generally starts 1 to 16 days after starting cephradine therapy. Gastrointestinal side effects have included nausea, vomiting. Hypersensitivity reactions have included rash, urticaria, pruritus, and joint pain. Bacteriostats may interfere with the bactericidal action of cephalosporins in acute infection; other agents, e.g., aminoglycosides, colistin, polymyxins, vancomycin, may increase the possibility of nephrotoxicity.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 30.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
27.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.61 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cutaneous vasculitis due to ciprofloxacin. | 1992 Jul 4 |
|
| Factors associated with antibiotic resistance in coliform organisms from community urinary tract infection in Wales. | 2001 Mar |
|
| [Antibiotic resistance of staphylococci isolated from outpatients]. | 2002 |
|
| Effect of UV-B radiation on some common antibiotics. | 2002 Apr |
|
| Initial study of using a laminar fluid diffusion interface for sample preparation in high-performance liquid chromatography. | 2002 Apr 19 |
|
| Clinical significance and epidemiology of NO-1, an unusual bacterium associated with dog and cat bites. | 2002 Feb |
|
| Regression of mucosa-associated lymphoid tissue lymphoma of the bladder after antibiotic therapy. | 2002 Feb 1 |
|
| Transport and utilization of arginine and arginine-containing peptides by rat alveolar macrophages. | 2002 Jun |
|
| Comparison of local povidone-iodine antisepsis with parenteral antibacterial prophylaxis for prevention of infective complications of TURP: a prospective randomized controlled study. | 2002 Mar |
|
| Evaluation of UV-radiation induced singlet oxygen generation potential of selected drugs. | 2002 May |
|
| Antimicrobial resistance pattern of Escherichia coli causing urinary tract infections, and that of human fecal flora, in the southeast of Iran. | 2002 Summer |
|
| Synthesis and antibacterial activity of cephradine metal complexes: part I complexes with magnesium, calcium, chromium and manganese. | 2003 Jan |
|
| Uptake of dipeptide and beta-lactam antibiotics by the basolateral membrane vesicles prepared from rat kidney. | 2003 Jan 10 |
|
| Sensitive determination of a beta-lactam antibiotic, cefaclor by liquid chromatography with chemiluminescence detection. | 2003 Jan 15 |
|
| Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: An eradication protocol. | 2003 Sep |
|
| Microbiology and drug sensitivity patterns of chronic suppurative otitis media. | 2004 Aug |
|
| Molecularly imprinted solid phase extraction-pulsed elution-mass spectrometry for determination of cephalexin and alpha-aminocephalosporin antibiotics in human serum. | 2004 Nov 15 |
|
| Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics. | 2004 Sep |
|
| Nateglinide uptake by a ceftibuten transporter in the rat kidney brush-border membrane. | 2005 Aug 30 |
|
| Synthesis and antibacterial activity of cephradine metal complexes : part II complexes with cobalt, copper, zinc and cadmium. | 2005 Jan |
|
| Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. | 2005 Jan |
|
| H+-dependent transport mechanism of nateglinide in the brush-border membrane of the rat intestine. | 2005 Jan |
|
| Purification and characterization of inducible cephalexin synthesizing enzyme in Gluconobacter oxydans. | 2005 Mar |
|
| Determination of ceftriaxone in cerebrospinal fluid by ion-pair liquid chromatography. | 2005 Mar-Apr |
|
| Systemic and local antibiotic prophylaxis in the prevention of Staphylococcus epidermidis graft infection. | 2005 Oct 21 |
|
| Preparation and characterization of uniform nanosized cephradine by combination of reactive precipitation and liquid anti-solvent precipitation under high gravity environment. | 2005 Sep 14 |
|
| [Bacterial pathogens and resistance patterns in community acquired pediatric urinary tract infection: experience of 152 cases]. | 2006 Apr |
|
| Increasing single and multi-antibiotic resistance in Shigella species isolated from shigellosis patients in Sana'a, Yemen. | 2006 Aug |
|
| Crystal form of cephradine. | 2006 Feb |
|
| A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean. | 2006 Feb 13 |
|
| Chemiluminescence flow-injection analysis of beta-lactam antibiotics using the luminol-permanganate reaction. | 2006 Jul-Aug |
|
| Cephradine antacids interaction studies. | 2007 Jul |
|
| Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. | 2007 Jul 15 |
|
| Determination of beta-lactam antibiotics in milk using micro-flow chemiluminescence system with on-line solid phase extraction. | 2007 Jun 5 |
|
| Characteristics of Streptococcus pyogenes strains isolated from Chinese children with scarlet fever. | 2008 Dec |
|
| Plasmid-mediated quinolone resistance in Salmonella enterica, United Kingdom. | 2008 Feb |
|
| [Prophylactic use of antibiotics in selective colorectal operation: a randomized controlled trial]. | 2008 Jan 15 |
|
| Pharmacokinetic study of cephradine in Pakistani healthy male volunteers. | 2008 Oct |
|
| Rapid and simple method for determination of cephradine in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS): application to the bioequivalence study. | 2009 Dec 1 |
|
| Antibiotics for mastitis in breastfeeding women. | 2009 Jan 21 |
|
| [Microcalorimetric investigation of two cephalosporins on colon bacteria activity]. | 2009 Oct |
|
| Traumatic optic neuropathy accompanying orbital grease gun injury. | 2010 Apr |
Patents
Sample Use Guides
For respiratory tract infections (other than lobar pneumonia) and skin and skin structure infections, the usual dose is 250 mg every 6 hours or 500 mg every 12 hours.
For lobar pneumonia, the usual dose is 500 mg every 6 hours or 1 g every 12 hours.
For uncomplicated urinary tract infections, the usual dose is 500 mg every 12 hours. In more serious urinary tract infections, including prostatitis, 500 mg every 6 hours or 1 g every 12 hours may be administered.
Larger doses (up to 1 g every 6 hours) may be given for severe or chronic infections.
Route of Administration:
Oral
| Substance Class |
Mixture
Created
by
admin
on
Edited
Mon Mar 31 18:19:16 GMT 2025
by
admin
on
Mon Mar 31 18:19:16 GMT 2025
|
| Record UNII |
F1BC02I72W
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
J01DB09
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
||
|
LIVERTOX |
178
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
||
|
NDF-RT |
N0000175488
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C47441
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
PRIMARY | |||
|
SUB21808
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
PRIMARY | |||
|
100000088255
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
PRIMARY | |||
|
D002515
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
PRIMARY | |||
|
CHEMBL1604
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
PRIMARY | |||
|
F1BC02I72W
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
PRIMARY | |||
|
SUB07417MIG
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
PRIMARY | |||
|
3547
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
PRIMARY | |||
|
4830
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
PRIMARY | |||
|
2239
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
PRIMARY | RxNorm | ||
|
Cephradine
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
PRIMARY | |||
|
1102805
Created by
admin on Mon Mar 31 18:19:16 GMT 2025 , Edited by admin on Mon Mar 31 18:19:16 GMT 2025
|
PRIMARY |
Any of these components may be present:
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE | |||
|
|
TRANSPORTER -> INHIBITOR |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Biological Half-life | PHARMACOKINETIC |
|
|
|||